M
Michael Lazarus
Researcher at Fresenius Medical Care
Publications - 11
Citations - 488
Michael Lazarus is an academic researcher from Fresenius Medical Care. The author has contributed to research in topics: Hemodialysis & Dialysis. The author has an hindex of 7, co-authored 11 publications receiving 442 citations.
Papers
More filters
Journal ArticleDOI
Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes
Eduardo Lacson,Weiling Wang,Cari DeVries,Keith Leste,Raymond M. Hakim,Michael Lazarus,Joseph Pulliam +6 more
TL;DR: Attending an options class predialysis was associated with more frequent selection of home dialysis, fewer tunneled HD catheters, and lower mortality risk during the first 90 days of dialysis therapy.
Journal ArticleDOI
Survival with Three-Times Weekly In-Center Nocturnal Versus Conventional Hemodialysis
Eduardo Lacson,Jianglin Xu,Rita S. Suri,Gihad Nesrallah,Robert M. Lindsay,Amit X. Garg,Keith Lester,Norma J. Ofsthun,Michael Lazarus,Raymond M. Hakim +9 more
TL;DR: Conversion to treatment with nocturnal hemodialysis associates with favorable clinical features, laboratory biomarkers, and improved survival compared with propensity score-matched controls, notwithstanding the possibility of residual selection bias.
Journal ArticleDOI
Hemodialysis access usage patterns in the incident dialysis year and associated catheter-related complications.
Hui Xue,Joachim H. Ix,Weiling Wang,Steven M. Brunelli,Michael Lazarus,Raymond M. Hakim,Eduardo Lacson +6 more
TL;DR: In a large and representative population of incident US dialysis patients, catheter use remains very high during the first year of HD care and is associated with high mechanical complication and bloodstream infection rates.
Journal ArticleDOI
Depressive symptoms associate with high mortality risk and dialysis withdrawal in incident hemodialysis patients
Eduardo Lacson,Nien-Chen Li,Sandie Guerra-Dean,Michael Lazarus,Raymond M. Hakim,Fredric O. Finkelstein +5 more
TL;DR: Depressive symptoms reported within the first 90 days of dialysis were associated with greater dialysis withdrawal and mortality risk over the succeeding year, and further evaluation for and treatment of depression during this early vulnerable period may improve symptoms, increase survival and decrease premature withdrawal from dialysis.
Journal ArticleDOI
Human Immunodeficiency Virus Infection in Hemodialysis Patients
B. Frank Polk,Alan Watson,Paul K. Whelton,W. Gordon Walker,Luis F. Gimenez,Ellen Taylor,Judith A. Britz,John H. Sadler,James Zachary,Gary Briefel,Cedric W. Bryan,James B. Carey,Pierre Forgacs,Wendell W. Hoffman,Patricia Murphy,Richard Platt,Michael Lazarus,Edgar L. Milford,Raymond M. Hakim,David R. Snydman,Andrew S. Levey,Ira B. Tager,Jerome E. Groopman +22 more
TL;DR: Serologic testing for either screening or case-finding purposes, dialysis procedures, renal transplantation, and seroepidemiologic research must be conducted with great attention to specificity; serum samples frozen for prolonged periods are especially likely to be nonspecifically ELISA positive.